Company Overview of Edge Therapeutics, Inc.
Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, designs and develops implantable technology for direct delivery of therapeutic compounds to the site of brain injury. Its drugs cover therapeutic areas, such as spontaneous brain hemorrhage, traumatic brain injuries, and brain surgeries. The company develops NimoGel and NimoVent to prevent delayed cerebral ischemia, a catastrophic delayed complication after subarachnoid hemorrhage. Its therapeutics are delivered to patients in the United States and internationally. The company was founded in 2009 and is based in New Providence, New Jersey.
139 South Street
New Providence, NJ 07974
Founded in 2009
Key Executives for Edge Therapeutics, Inc.
Chief Accounting and Operations Officer
Compensation as of Fiscal Year 2014.
Edge Therapeutics, Inc. Key Developments
Edge Therapeutics Initiates Enrollment of Second Cohort in Phase 1/2 NEWTON Study of EG-1962 for Improvement of Outcome after Ruptured Brain Aneurysm
Jun 5 14
Edge Therapeutics announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962. The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). The company is also assessing patient functional outcomes at 30 and 90 days, which it believes will be indicative of the potential efficacy of EG-1962. EG-1962 is a novel polymeric nimodipine microparticle utilizing Edge's proprietary Precisa(TM) development platform and is being developed to improve patient outcome after aSAH, also commonly referred to as ruptured brain aneurysm.
Edge Therapeutics, Inc. Announces Opening of New Corporate Headquarters
Apr 8 14
Edge Therapeutics, Inc. announced that the company has opened its new corporate headquarters at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey.
Edge Therapeutics Announces Executive Appointments
Apr 8 14
Edge Therapeutics announced the appointment and promotion of key executives to its senior management team to strengthen the Company's leadership. Herbert J. Faleck, D.O. has joined Edge as Chief Medical Officer; Andrew J. Einhorn as Chief Financial Officer; Alpaslan Yaman, Ph.D. as Vice President, Operations and Manufacturing, Gene Mack as Senior Director, Investor Relations, and William Shatynski as Senior Director, Financial Reporting and Controller. Additionally, Albert Marchio has been appointed to the expanded role of Chief Accounting and Operations Officer for the Company. Dr. Faleck, a pediatric neurologist, has more than 25 years of experience in clinical research. Prior to joining Edge, he was the Chief Medical Officer of Celgene Cellular Therapeutics where he led the clinical, medical, regulatory and organizational development for a key division of Celgene Corporation. Mr. Einhorn has more than 10 years of experience in the pharmaceutical industry in the development and execution of corporate strategy. Prior to joining Edge, he served as co-founder and Chief Financial Officer for three specialty pharmaceutical and therapeutics companies: Oceana Therapeutics, Inc., Esprit Pharma, and ESP Pharma, where he was involved in numerous financing, acquisition and licensing transactions across a variety of therapeutic areas and geographies, and played a key role in the ultimate sale of those companies to larger pharmaceutical companies. Prior to Edge, Mr. Mack was a Senior Biotechnology Analyst at Brean Capital and spent the majority of his career at Lazard Capital Markets. Prior to joining Edge, Mr. Shatynski was Senior Director and Controller at Insmed Inc. where he was responsible for internal and external financial reporting, Sarbanes-Oxley 404 compliance and SEC filings. Dr. Yaman has more than 28 years of biotech, pharmaceutical and medical device industry experience in sterile and non-sterile formulation development, process development and scale-up, validation, technology transfer and technical services with specific experience in sterile microparticle process design and scale-up. Dr. Yaman worked for Johnson & Johnson in Product Support/Technical Services and Schering Plough as Director, Pharmaceutical Technology Transfer and Global Technical Services.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|